Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.638.090 [Categoria DeCS]
Referências encontradas : 323 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 33 ir para página                         

  1 / 323 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337676
[Au] Autor:Pajic NZB; Todosijevic MN; Vuleta GM; Cekic ND; Dobricic VD; Vucen SR; Calija BR; Lukic MZ; Ilic TM; Savic SD
[Ad] Endereço:1Department of Pharmaceutical Technology and Cosmetology Faculty of Medicine, University of Banja Luka, 78000 Banja Luka Bosnia and Herzegovina.
[Ti] Título:Alkyl polyglucoside vs. ethoxylated surfactant-based microemulsions as vehicles for two poorly water-soluble drugs: physicochemical characterization and in vivo skin performance.
[So] Source:Acta Pharm;67(4):415-439, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Two types of biocompatible surfactants were evaluated for their capability to formulate skin-friendly/non-irritant microemulsions as vehicles for two poorly water-soluble model drugs differing in properties and concentrations: alkyl polyglucosides (decyl glucoside and caprylyl/capryl glucoside) and ethoxylated surfactants (glycereth-7-caprylate/ caprate and polysorbate 80). Phase behavior, structural inversion and microemulsion solubilization potential for sertaconazole nitrate and adapalene were found to be highly dependent on the surfactants structure and HLB value. Performed characterization (polarized light microscopy, pH, electrical conductivity, rheological, FTIR and DSC measurements) indicated a formulation containing glycereth- 7-caprylate/caprate as suitable for incorporation of both drugs, whereas alkyl polyglucoside-based systems did not exhibit satisfying solubilization capacity for sertaconazole nitrate. Further, monitored parameters were strongly affected by sertaconazole nitrate incorporation, while they remained almost unchanged in adapalene-loaded vehicles. In addition, results of the in vivo skin performance study supported acceptable tolerability for all investigated formulations, suggesting selected microemulsions as promising carriers worth exploring further for effective skin delivery of model drugs.
[Mh] Termos MeSH primário: Caprilatos/farmacocinética
Emulsões/farmacologia
Glucosídeos/farmacologia
Veículos Farmacêuticos/farmacocinética
Polissorbatos/farmacologia
Pele/metabolismo
Tensoativos/farmacologia
[Mh] Termos MeSH secundário: Adapaleno/farmacologia
Administração Cutânea
Adulto
Caprilatos/química
Emulsões/química
Glucosídeos/química
Seres Humanos
Imidazóis/farmacologia
Microscopia de Polarização
Veículos Farmacêuticos/química
Polissorbatos/química
Pele/efeitos dos fármacos
Testes de Irritação da Pele
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
Tensoativos/química
Tiofenos/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Caprylates); 0 (Emulsions); 0 (Glucosides); 0 (Imidazoles); 0 (Pharmaceutical Vehicles); 0 (Polysorbates); 0 (Surface-Active Agents); 0 (Thiophenes); 1L4806J2QF (Adapalene); 72W71I16EG (sertaconazole); Z17H97EA6Y (decyl glucoside)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  2 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27743393
[Au] Autor:Kurokawa I; Oiso N; Kawada A
[Ad] Endereço:Department of Dermatology and Acne Clinical Research Center, Meiwa Hospital, Nishinomiya, Japan.
[Ti] Título:Adjuvant alternative treatment with chemical peeling and subsequent iontophoresis for postinflammatory hyperpigmentation, erosion with inflamed red papules and non-inflamed atrophic scars in acne vulgaris.
[So] Source:J Dermatol;44(4):401-405, 2017 Apr.
[Is] ISSN:1346-8138
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The standard management of acne vulgaris in Japan includes a combination of topical treatment with benzoyl peroxide (BPO) and BPO/clindamycin (CLDM), topical adapalene and systemic antimicrobials. However, the treatment of therapy-resistant complications such as postinflammatory hyperpigmentation (PIH), erosions with inflamed red papules and atrophic scars has not been established. We performed chemical peeling with glycolic acid and iontophoresis with ascorbyl 2-phosphate 6-palmitate and DL-α-tocopherol phosphate for the treatment of PIH, erosions with inflamed red papules and non-inflamed atrophic scars in 31 patients with acne vulgaris (mild to severe severity), and evaluated the efficacy and safety of these interventions. In most of cases, there was remarkable improvement in PIH and erosions with inflamed red papules after treatment. There was also some improvement in non-inflamed atrophic scars without erythema. Mild redness and irritation was observed in four cases as adverse reactions. Early initial treatment of PIH and erosions with red papules by chemical peeling and iontophoresis is an effective and safe method to prevent the formation of atrophic scars in patients with acne vulgaris.
[Mh] Termos MeSH primário: Acne Vulgar/complicações
Acne Vulgar/terapia
Abrasão Química/efeitos adversos
Cicatriz/terapia
Eritema/terapia
Hiperpigmentação/terapia
Iontoforese/efeitos adversos
[Mh] Termos MeSH secundário: Adapaleno/uso terapêutico
Adolescente
Adulto
Anti-Infecciosos/uso terapêutico
Ácido Ascórbico/administração & dosagem
Ácido Ascórbico/efeitos adversos
Ácido Ascórbico/análogos & derivados
Ácido Ascórbico/uso terapêutico
Atrofia
Peróxido de Benzoíla/uso terapêutico
Cicatriz/patologia
Clindamicina/uso terapêutico
Terapia Combinada
Feminino
Glicolatos/administração & dosagem
Glicolatos/efeitos adversos
Glicolatos/uso terapêutico
Seres Humanos
Japão
Masculino
Índice de Gravidade de Doença
Resultado do Tratamento
Adulto Jovem
alfa-Tocoferol/administração & dosagem
alfa-Tocoferol/efeitos adversos
alfa-Tocoferol/análogos & derivados
alfa-Tocoferol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (6-O-palmitol-ascorbate-2-O-phosphate); 0 (Anti-Infective Agents); 0 (Glycolates); 0WT12SX38S (glycolic acid); 1L4806J2QF (Adapalene); 38976-17-9 (alpha-tocopherol phosphate); 3U02EL437C (Clindamycin); H4N855PNZ1 (alpha-Tocopherol); PQ6CK8PD0R (Ascorbic Acid); W9WZN9A0GM (Benzoyl Peroxide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161016
[St] Status:MEDLINE
[do] DOI:10.1111/1346-8138.13634


  3 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27565687
[Au] Autor:Ramezanli T; Zhang Z; Michniak-Kohn BB
[Ad] Endereço:Ernest Mario School of Pharmacy, Rutgers - The State University of New Jersey, Piscataway, NJ, USA; Center for Dermal Research, Rutgers - The State University of New Jersey, Piscataway, NJ, USA.
[Ti] Título:‬‬‬‬‬‬‬‬Development and characterization of polymeric nanoparticle-based formulation of adapalene for topical acne therapy‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬.
[So] Source:Nanomedicine;13(1):143-152, 2017 Jan.
[Is] ISSN:1549-9642
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this study is to develop a new formulation of adapalene for the topical treatment of acne. We investigated applicability of polymeric nanocarriers based on tyrosine-derived nanospheres (TyroSpheres) for adapalene delivery. TyroSpheres effectively encapsulated adapalene and substantially enhanced its aqueous solubility, while decreasing the crystallinity of the drug in the formulation. Skin distribution of adapalene via TyroSphere formulation was evaluated ex vivo using human cadaver and porcine ear skin, and this was compared with the commercial adapalene formulation, Differin®. Sustained drug release across stratum corneum in 51 h was observed from TyroSpheres. Additionally, in vitro skin irritation studies demonstrated that encapsulation of adapalene in TyroSpheres significantly reduced the irritancy of the drug to monolayer HaCaTs and reconstituted human epidermis (EpiDerm™, MatTek Corp.). The results suggest that TyroSpheres provide a promising carrier system to deliver hydrophobic drugs to hair follicles and upper epidermis while minimizing skin irritation of the encapsulated drug.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Adapaleno/administração & dosagem
Nanosferas/química
Absorção Cutânea
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Liberação Controlada de Fármacos
Folículo Piloso/metabolismo
Seres Humanos
Polímeros/química
Pele/metabolismo
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Polymers); 1L4806J2QF (Adapalene)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160828
[St] Status:MEDLINE


  4 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27649343
[Ti] Título:In brief: An over-the-counter retinoid for acne.
[So] Source:Med Lett Drugs Ther;58(1504):126, 2016 Sep 26.
[Is] ISSN:1523-2859
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Adapaleno/administração & dosagem
Fármacos Dermatológicos/administração & dosagem
Medicamentos sem Prescrição/administração & dosagem
Retinoides/administração & dosagem
[Mh] Termos MeSH secundário: Acne Vulgar/diagnóstico
Adapaleno/química
Administração Tópica
Fármacos Dermatológicos/química
Seres Humanos
Medicamentos sem Prescrição/química
Retinoides/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Nonprescription Drugs); 0 (Retinoids); 1L4806J2QF (Adapalene)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170201
[Lr] Data última revisão:
170201
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160921
[St] Status:MEDLINE


  5 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27565163
[Au] Autor:Joshi P; Kooshki M; Aldrich W; Varghai D; Zborowski M; Singh AD; Triozzi PL
[Ad] Endereço:Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA.
[Ti] Título:Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.
[So] Source:Clin Exp Metastasis;33(8):829-838, 2016 Dec.
[Is] ISSN:1573-7276
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Natural killer (NK) cells are implicated in the control of metastasis in uveal melanoma, a process that has been ascribed to its cancer stem cell subpopulation. NK cell activation is regulated by specific microRNA (miR). The NK cell sensitivity and regulatory miR production of uveal melanoma cancer stem cells was examined. Cancer stem cells enriched from aggressively metastatic MUM2B uveal melanoma cells by selecting CD271 cells or propagating as non-adherent spheres in stem-cell supportive were more resistant to NK cell cytolysis than cancer stem cells enriched from less aggressively metastatic OCM1 uveal melanoma cells. Both MUM2B and OCM1 cells expressed and secreted NK cell regulatory miRs, including miR 146a, 181a, 20a, and 223. MUM2B cells expressed and secreted miR-155; OCM1 cells did not. Transfecting MUM2B cells with anti-miR-155 increased NK cell sensitivity. CD271 cells were identified in the blood of patients with metastatic uveal melanoma and were characterized by low expression of melanocyte differentiation determinants and by the ability to form non-adherent spheres in stem-cell supportive media. These cells also expressed NK cell regulatory miRs, including miR-155. These results indicate that uveal melanoma cancer stem cells can vary in their sensitivity to NK cell lysis and their expression of NK cell regulatory miRs. Circulating CD271 cells from patients with metastatic uveal melanoma manifest cancer stem cell features and express miRs associated with NK cell suppression, including miR-155, that may contribute to metastatic progression.
[Mh] Termos MeSH primário: Células Matadoras Naturais/patologia
Melanoma/genética
MicroRNAs/genética
Células-Tronco Neoplásicas/metabolismo
Neoplasias Uveais/genética
[Mh] Termos MeSH secundário: Adapaleno/imunologia
Adapaleno/metabolismo
Citotoxicidade Imunológica/imunologia
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Células Matadoras Naturais/metabolismo
Melanócitos/patologia
Melanoma/patologia
MicroRNAs/biossíntese
Células-Tronco Neoplásicas/patologia
Transfecção
Neoplasias Uveais/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MIRN155 microRNA, human); 0 (MicroRNAs); 1L4806J2QF (Adapalene)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160828
[St] Status:MEDLINE


  6 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27529709
[Au] Autor:Tangjaturonrusamee C; Rattanaumpawan P; Ditre CM
[Ad] Endereço:Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand.
[Ti] Título:Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne.
[So] Source:Cutis;98(1):56-61, 2016 Jul.
[Is] ISSN:2326-6929
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acne vulgaris is a common and distressing condition that typically presents in adolescents and young adults. The aim of this split-face, single-blind, randomized, controlled study was to determine if combination therapy with pneumatic broadband light (PBBL) plus adapalene gel 0.3% is superior to adapalene gel 0.3% monotherapy in the treatment of acne. Results indicated that the addition of PBBL to topical regimens may lead to quicker results and therefore may improve treatment adherence to topical therapies in acne patients.
[Mh] Termos MeSH primário: Acne Vulgar
Adapaleno/administração & dosagem
Fototerapia/métodos
[Mh] Termos MeSH secundário: Acne Vulgar/diagnóstico
Acne Vulgar/tratamento farmacológico
Acne Vulgar/psicologia
Acne Vulgar/radioterapia
Adulto
Terapia Combinada/métodos
Fármacos Dermatológicos/administração & dosagem
Feminino
Seres Humanos
Masculino
Monitorização Fisiológica/métodos
Cooperação do Paciente
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 1L4806J2QF (Adapalene)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE


  7 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27416308
[Au] Autor:Yeh L; Bonati LM; Silverberg NB
[Ad] Endereço:Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
[Ti] Título:Topical retinoids for acne.
[So] Source:Semin Cutan Med Surg;35(2):50-6, 2016 Jun.
[Is] ISSN:1085-5629
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Topical retinoids are currently approved by the US Food and Drug Administration for the treatment of acne vulgaris in nonpregnant, nonlactating patients 12 years of age and older. Their efficacy, safety, and tolerability are well documented for inflammatory and noninflammatory acne with studies repeatedly demonstrating a decrease in the number of lesions, significant improvement in acne severity, improvement in the cosmetic appearance of acne, and the prevention of acne lesions through microcomedone formation. There is some variability between prescription retinoid products regarding efficacy, safety, and tolerability; with erythema, peeling, and dryness being common, potential side effects. Due to their efficacious and safe profile, topical retinoids remain the first-line treatment for acne vulgaris.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Adapaleno/administração & dosagem
Fármacos Dermatológicos/uso terapêutico
Retinoides/administração & dosagem
Tretinoína/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Seres Humanos
Ácidos Nicotínicos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Nicotinic Acids); 0 (Retinoids); 1L4806J2QF (Adapalene); 5688UTC01R (Tretinoin); 81BDR9Y8PS (tazarotene)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160715
[Lr] Data última revisão:
160715
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160715
[St] Status:MEDLINE
[do] DOI:10.12788/j.sder.2016.024


  8 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27281440
[Au] Autor:Czilli T; Tan J; Knezevic S; Peters C
[Ad] Endereço:Private practice, Family Medicine, Windsor, ON, Canada.
[Ti] Título:Cost of Medications Recommended by Canadian Acne Clinical Practice Guidelines.
[So] Source:J Cutan Med Surg;20(6):542-545, 2016 Nov.
[Is] ISSN:1615-7109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acne affects a large proportion of the Canadian population and has psychosocial and financial consequences. OBJECTIVE: We provide cost information for treatments recommended by the Canadian acne guidelines. METHODS: Highest level recommendations were selected for 3-month usage cost. RESULTS: Three-month estimated treatment costs were as follows: topical retinoids ($14.40-$73.80), benzoyl peroxide (BPO; $6.75), fixed-dose BPO-clindamycin ($40.95-$44.10) and BPO-adapalene ($73.80), oral antibiotics ($25.20 for tetracycline 250 mg qid; $52.20 and $52.74 for doxycycline 50 mg bid and 100 mg od, respectively), and hormonal therapy ($26.46-$37.80 for ethinyl estradiol [EE] 0.030 mg/drospirenone 3mg and $75.60-108.99 for EE 0.035 mg/cyproterone acetate 2 mg). Oral isotretinoin 3-month costs ranged from $393.96 to $478.80. CONCLUSIONS: Awareness of costs of recommended treatments may facilitate improved outcomes by increasing procurement and adherence.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Acne Vulgar/economia
Antibacterianos/economia
Peróxido de Benzoíla/economia
Fármacos Dermatológicos/economia
[Mh] Termos MeSH secundário: Adapaleno/economia
Administração Cutânea
Administração Oral
Antagonistas de Androgênios/economia
Androstenos/economia
Antibacterianos/administração & dosagem
Canadá
Clindamicina/administração & dosagem
Clindamicina/economia
Acetato de Ciproterona/economia
Doxiciclina/administração & dosagem
Doxiciclina/economia
Combinação de Medicamentos
Estrogênios/economia
Etinilestradiol/economia
Seres Humanos
Isotretinoína/administração & dosagem
Isotretinoína/economia
Antagonistas de Receptores de Mineralocorticoides/economia
Minociclina/administração & dosagem
Minociclina/economia
Guias de Prática Clínica como Assunto
Índice de Gravidade de Doença
Tetraciclina/administração & dosagem
Tetraciclina/economia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Androstenes); 0 (Anti-Bacterial Agents); 0 (Dermatologic Agents); 0 (Drug Combinations); 0 (Estrogens); 0 (Mineralocorticoid Receptor Antagonists); 1L4806J2QF (Adapalene); 3U02EL437C (Clindamycin); 423D2T571U (Ethinyl Estradiol); 4KM2BN5JHF (Cyproterone Acetate); EH28UP18IF (Isotretinoin); F8VB5M810T (Tetracycline); FYY3R43WGO (Minocycline); N12000U13O (Doxycycline); N295J34A25 (drospirenone); W9WZN9A0GM (Benzoyl Peroxide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160610
[St] Status:MEDLINE


  9 / 323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27272079
[Au] Autor:Bhatia N; Bhatt V; Martin G; Pillai R
[Ti] Título:Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period.
[So] Source:J Drugs Dermatol;15(6):721-6, 2016 Jun 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Topical therapy of acne vulgaris (acne) is very common, however cutaneous tolerability can influence patient adherence, and concerns about skin irritation have lead to a number of comparative split-face studies. Advances in formulation technology have provided new fixed combinations with lower concentrations of potentially irritating ingredients without compromising efficacy. These developments now afford the opportunity to formulate fixed combinations with higher concentrations of active ingredients that may provide the greater efficacy needed in more severe disease with good tolerability.
Here, we compare the tolerability of two such developments, clindamycin-BP 3.75% gel and adapalene 0.3%-BP 2.5% gel, in healthy volunteers with no apparent facial redness or dryness over 21-days, using a split-face methodology.
Clindamycin-BP 3.75% gel was more tolerable than adapalene 0.3%-BP 2.5% gel over the duration of the two studies, with statistically significant differences in cumulative change from baseline starting as early as day 4 (stinging), day 5 (erythema, dryness, and scaling), day 6 (burning), and day 8 (itching); and in composite irritation index (stinging, erythema, dryness, scaling, burning, and itching) from day 4. Transepidermal water loss was less with clindamycin-BP 3.75% gel (statistically significant from day 8). Adverse events were twice as common with adapalene 0.3%-BP 2.5% gel.
These data suggest that clindamycin-BP 3.75% gel is likely to be better tolerated than adapalene 0.3%-BP 2.5% gel in moderate-to-severe acne.

J Drugs Dermatol. 2016;15(6):721-726.
[Mh] Termos MeSH primário: Acne Vulgar/diagnóstico
Acne Vulgar/tratamento farmacológico
Adapaleno/administração & dosagem
Clindamicina/administração & dosagem
Dermatite Irritante/diagnóstico
Dermatite Irritante/etiologia
[Mh] Termos MeSH secundário: Adapaleno/efeitos adversos
Administração Cutânea
Adulto
Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Clindamicina/efeitos adversos
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Método Duplo-Cego
Esquema de Medicação
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Dermatologic Agents); 0 (Drug Combinations); 1L4806J2QF (Adapalene); 3U02EL437C (Clindamycin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170426
[Lr] Data última revisão:
170426
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE


  10 / 323 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27220773
[Au] Autor:Dressler C; Rosumeck S; Nast A
[Ad] Endereço:Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Charitx00E9; - Universitx00E4;tsmedizin Berlin, Berlin, Germany.
[Ti] Título:How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy.
[So] Source:Dermatology;232(3):371-80, 2016.
[Is] ISSN:1421-9832
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:After cessation of successful initial acne therapy, patients often experience flares. Consecutive maintenance treatment after successful induction therapy is promoted by guidelines; however, little is known about the efficacy/safety of different maintenance regimens. A systematic review on acne maintenance treatments was conducted. We identified 5 randomized controlled trials [RCTs; adapalene vs. vehicle or vs. no treatment (3 RCTs), adapalene/benzoyl peroxide (BPO) vs. vehicle, combination/monotherapy of minocycline (systemic)/tazarotene/placebo] and 3 non-RCTs on systemic isotretinoin, adapalene/BPO and azelaic acid. The results of adapalene versus vehicle/no treatment varied depending on the reported outcome. The 'number of patients maintaining at least 50% improvement' counting inflammatory lesions/non-inflammatory lesions with adapalene was superior to vehicle (risk ratio, RR 1.24, 95% confidence interval, CI 1.08-1.43/RR 1.34, 95% CI 1.18-1.59). However, no significant differences were found in 2 of 3 RCTs for maintaining 'clear/almost clear' or 'mild acne' or on the global grading score. For the combination regimens of minocycline/tazarotene/placebo, no significant differences were found. Adapalene/BPO was superior to vehicle counting inflammatory lesions/non-inflammatory lesions (RR 1.61, 95% CI 1.31-1.99; RR 1.80, 95% CI 1.44-2.26). Due to the scarcity of studies, few conclusions can be drawn. More homogeneous outcome measures and specific maintenance study designs may lead to more robust findings.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Fármacos Dermatológicos/administração & dosagem
[Mh] Termos MeSH secundário: Adapaleno/administração & dosagem
Administração Cutânea
Peróxido de Benzoíla/administração & dosagem
Géis
Seres Humanos
Isotretinoína/administração & dosagem
Ácidos Nicotínicos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Gels); 0 (Nicotinic Acids); 1L4806J2QF (Adapalene); 81BDR9Y8PS (tazarotene); EH28UP18IF (Isotretinoin); W9WZN9A0GM (Benzoyl Peroxide)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160526
[St] Status:MEDLINE
[do] DOI:10.1159/000446069



página 1 de 33 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde